Le Lézard
Classified in: Health, Science and technology
Subject: TDS

At-Home Vision Monitoring App May Improve Patient Care


NEW ORLEANS, Nov. 12, 2017 /PRNewswire/ -- Patients with age-related macular degeneration or diabetic retinopathy who used a mobile application to test their vision at home got comparable results to in-office vision testing, according to research presented today at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology. The findings suggest that the smartphone app may help patients take better care of their vision.

AAO Logo (PRNewsFoto/American Academy of Ophthalmology)

Ophthalmologists ? physicians who specialize in medical and surgical eye care ? have effective treatment options for AMD and diabetic retinopathy that slow or prevent vision loss. But treatment is most effective when it's given at the earliest signs of disease.

That's why ophthalmologists often ask their patients to check their vision at home with a test called the Amsler grid. It is a simple square on a sheet of paper containing a grid pattern and a dot in the middle. When used correctly, it can show problem spots in a patient's field of vision. However, research shows that patients often fail to use the Amsler grid between office visits, and patients find it difficult to use effectively.

The app, known as Checkup, is designed to engage patients with their health care. Patients use it to assess their vision as often as their ophthalmologist prescribes. The voice-activated app also sends reminders to a patient's device if they forget to test on schedule. Results of the test are sent in real time to a secure cloud-based data warehouse. The ophthalmologist can view the results, and contact the patient if they detect a deterioration in their vision.

Researchers at Northern California Retina Vitreous Associates in Mountain View, Calif., wanted to find out if a smartphone app can monitor patients' vision at home as accurately as vision testing in the ophthalmologist's office, so they asked 27 patients with either AMD or diabetic retinopathy to use the app for two months.

Patients tested their vision at home using the app, and were then re-tested in the office. There was strong agreement between the Checkup app and the in-office tests for both visual acuity and Amsler grid testing. Every patient reported that it was easy to use.

Linda Redington, 57, and her 83-year-old mother, Ethel Redington, were part of the study. They both have AMD. They said it was easy to set up on their phones and easy to use. Both Linda and Ethel tested their vision with a basic visual acuity test and the Amsler grid test.

"I never missed a day," Linda Redington said. "It was easy and it didn't take a big chunk out of the day. It took just five minutes."

She says that the Amsler grid test on the app was easier to use than the static, black dot on a piece of paper. Instead of wielding a pen and piece of paper, the app serves up a red, flashing light that she simply taps with her finger.

"We're excited about the potential of this technology to improve patient care," said lead researcher, Rahul N. Khurana, M.D. "More and larger studies are required to make sure it works as well as our small study showed. But we found that it encouraged patients to take a more active role in their care, and they found it easy to use."

About the American Academy of Ophthalmology
The American Academy of Ophthalmology is the world's largest association of eye physicians and surgeons. A global community of 32,000 medical doctors, we protect sight and empower lives by setting the standards for ophthalmic education and advocating for our patients and the public. We innovate to advance our profession and to ensure the delivery of the highest-quality eye care. Our EyeSmart® program provides the public with the most trusted information about eye health. For more information, visit aao.org.

SOURCE American Academy of Ophthalmology


These press releases may also interest you

at 07:35
Cybin Inc. (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced...

at 07:30
MedBright AI Investments Inc. (the "Company" or "MedBright") today announced that Dermatology Institute & Skin Care Center (DISCC) has signed a 3 year contract to use the MedMatrix AI Platform, including all 5 product modules in their single clinic...

at 07:30
UniDoc Health Corp. (FRA: L7T) ("UniDoc," or the "Company"), an innovator in the eHealth sector, proudly announces the deployment of an H3 Health Cube to Ketchikan, Alaska. This initiative, in collaboration with Planet Defense, LLC, marks a...

at 07:30
Virax Biolabs Group Limited ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today that it will be hosting a booth at the European Society of...

at 07:25
Cardiawave SA, a French Medtech company that has developed an innovative Non-Invasive Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis, is delighted to announce the appointment of Olivier Pierron as...

at 07:15
Arch Biopartners Inc., ("Arch" or the "Company") , announced today that a research team from St. Michael's Hospital, a site of Unity Health Toronto, has joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac...



News published on and distributed by: